Journal of Cystic Fibrosis 2024

6 papers
The 2024 volume of the *Journal of Cystic Fibrosis* focuses on the intersection of genetic modifiers and clinical management strategies. Research themes include the use of aggregated genetic modifiers to predict lung function in pediatric patients and the influence of genetic factors on Vitamin D status and supplement response. Technological developments in gene therapy are also featured, specifically regarding the integration of transgenes through the Find and cut-and-transfer (FiCAT) method. Clinical research from this year examines the real-world effectiveness of *Pseudomonas aeruginosa* eradication protocols and shifts in inhaled antibiotic prescription patterns in the United States. Other studies investigate how pharmacological improvements in CFTR function restore airway epithelial homeostasis and host defense. Notable contributors to these findings include HuiChuan J. Lai, Philip M. Farrell, and Qiongshi Lu. These papers provide data on both the molecular mechanisms of cystic fibrosis and the evolving landscape of therapeutic interventions.

Top Authors

AuthorPapers
Qiongshi Lu2
Irina Lehmann1
Roland Eils1

Papers

Title
514 Real-word effectiveness of a Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis
836 Aggregated genetic modifiers predict lung function in childrenwith CF aged 5 to 6
Changes in factors associated with inhaled antibiotic prescriptions for people with cystic fibrosis over time in the U.S.
Vitamin D status and variable responses to supplements depend in part on genetic factors in adults with cystic fibrosis
WS05.03 Pharmacological improvement of CFTR function rescues airway epithelial homeostasis and host defense in children with cystic fibrosis
WS05.06 Integration of the LacZ and CFTR transgene using Find and cut-and-transfer (FiCAT)